Magazine Article | January 3, 2023

Companies To Watch: Ocelot Bio

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Focusing a single drug on multiple complications of end-stage liver disease

Ocelot Bio is developing a drug, coded OCE-205, to target multiple complications of end-stage liver disease (ESLD). Ocelot’s lead program, now in a Phase 2 trial, addresses hepatorenal syndrome with acute kidney injury (HRS-AKI). A second program, addressing ascites in the liver, is advancing in preclinical testing for indication and formulation. Ascites, or excess fluid in the peritoneal cavity, is the most common complication of advanced “decompensated” cirrhosis. The central stalk branching into most of the drug’s therapeutic targets is portal hypertension, the common disease mechanism for the various conditions. The entirely “remote” operating company plans to keep its sole focus on OCE-205 for now.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader